EOMES

2 papers2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funder: Israel Science Foundation

Animals1
In silico1

Effects

Liver fibrosis

downin mice1

1 study

EOMES decreases liver fibrosis in mice.
“In liver cirrhosis, a model of localized chronic inflammation, CD4-Eomes cell elimination increased fibrosis, SC load and worsened the disease.”
Animalsin liver cirrhosis, shown by deletion of Eomes in CD4 T cells
CD4 T cells acquire Eomesodermin to modulate cellular senescence and aging
Nature aging7 Oct 2025

Lifespan

upin mice1

1 study

EOMES extends lifespan in mice.
“eliminating CD4-Eomes cells at advanced age by selectively deleting the Eomes transcription factor in CD4 T cells results in increased accumulation of SCs, profound physical deterioration and a decreased lifespan.”
Animalsshown by selective deletion of Eomes in CD4 T cells at advanced age
CD4 T cells acquire Eomesodermin to modulate cellular senescence and aging
Nature aging7 Oct 2025